These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17515569)

  • 21. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of bisphosphonates in multiple myeloma.
    Mahindra A; Pozzi S; Raje N
    Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone disease in myeloma.
    Berenson JR
    Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
    J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Palmieri C; Fullarton JR; Brown J
    Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
    Zervas K; Verrou E; Teleioudis Z; Vahtsevanos K; Banti A; Mihou D; Krikelis D; Terpos E
    Br J Haematol; 2006 Sep; 134(6):620-3. PubMed ID: 16889620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
    Dickinson M; Prince HM; Kirsa S; Zannettino A; Gibbs SD; Mileshkin L; O'Grady J; Seymour JF; Szer J; Horvath N; Joshua DE
    Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonates in multiple myeloma.
    Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
    Cochrane Database Syst Rev; 2002; (3):CD003188. PubMed ID: 12137679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates in multiple myeloma.
    Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
    Cochrane Database Syst Rev; 2001; (4):CD003188. PubMed ID: 11687178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Gabbert TI; Hoffmeister B; Felsenberg D
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.